Based on the HUTCHMED DRC stock forecast from 1 analysts, the average analyst target price for HUTCHMED DRC is USD 19.00 over the next 12 months. HUTCHMED DRC’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of HUTCHMED DRC is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, HUTCHMED DRC’s stock price was USD 14.27. HUTCHMED DRC’s stock price has changed by -0.28% over the past week, -15.81% over the past month and -21.20% over the last year.
No recent analyst target price found for HUTCHMED DRC
No recent average analyst rating found for HUTCHMED DRC
Company Overview HUTCHMED DRC
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. Read Less
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell...Read More
Frequently Asked Questions About HUTCHMED DRC (HCM) Stock
Based on ratings from 1 analysts HUTCHMED DRC's stock is Hold . Stock Target Advisor's fundamental analysis is Neutral. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on HCM's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for HCM is USD 19.00 over the next 12 months. The maximum analyst target price is USD 19 while the minimum anlayst target price is USD 19.
HCM stock's Price/Earning ratio is 30.00.
Our analysis grades HCM stock's Price / Earning ratio at F. This means that HCM stock's Price/Earning ratio is above 48% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this HCM may be fairly valued for its sector
The last closing price of HCM's stock was USD 14.27.
The most recent market capitalization for HCM is USD 2.94B.
Based on targets from 1 analysts, the average taret price for HCM is projected at USD 19.00 over the next 12 months.
This means that HCM's stock price may go up by +33.15% over the next 12 months.
We can't find any ETFs which contains HUTCHMED DRC's stock.
As per our most recent records HUTCHMED DRC has 1,970 Employees.
HUTCHMED DRC's registered address is Cheung Kong Center, Hong Kong, Hong Kong.
You can get more information about it from HUTCHMED DRC's website at https://www.hutch-med.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About HUTCHMED DRC (HCM) Stock
Based on ratings from 1 analysts HUTCHMED DRC's stock is Hold . Stock Target Advisor's fundamental analysis is Neutral. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on HCM's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for HCM is USD 19.00 over the next 12 months. The maximum analyst target price is USD 19 while the minimum anlayst target price is USD 19.
HCM stock's Price/Earning ratio is 30.00.
Our analysis grades HCM stock's Price / Earning ratio at F. This means that HCM stock's Price/Earning ratio is above 48% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this HCM may be fairly valued for its sector
The last closing price of HCM's stock was USD 14.27.
The most recent market capitalization for HCM is USD 2.94B.
Based on targets from 1 analysts, the average taret price for HCM is projected at USD 19.00 over the next 12 months.
This means that HCM's stock price may go up by +33.15% over the next 12 months.
We can't find any ETFs which contains HUTCHMED DRC's stock.
As per our most recent records HUTCHMED DRC has 1,970 Employees.
HUTCHMED DRC's registered address is Cheung Kong Center, Hong Kong, Hong Kong.
You can get more information about it from HUTCHMED DRC's website at https://www.hutch-med.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HCM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
